Moderna's Melanoma Data Land, but the Market Was Betting on More
Published on 10/23/2026 at 06:11 | Editorial boerse-global.de
Moderna and Merck have delivered a genuine clinical result in high-risk melanoma. What they have not delivered is a reason for investors to stop asking what is already priced in. The stock fell 17% on the news, and the gap between those two facts is the whole story.
The trigger was messy. Reports of prematurely leaked results on the personalized cancer vaccine Intismeran autogene, developed with Merck, sent the shares gyrating hard enough that trading was briefly halted for volatility. The companies then published the data ahead of schedule. That early release changes nothing about the science behind the numbers.
What the trial actually showed
The Phase 3 INTerpath-001 study enrolled 1,137 patients whose high-risk melanoma had been completely removed surgically. Median follow-up stood at 24.6 months. Against Keytruda alone, the combination cut the risk of recurrence or death by 42%. The risk of distant metastasis or death fell by 38%.
At the two-year mark, 82.2% of patients on the combination were relapse-free, compared with 70.0% on Keytruda by itself. No new safety signals were reported. Reuters likewise described a clear advantage for the combination — this is not a clinical failure by any reasonable reading.
The caveats matter just as much. Overall survival data are not yet mature, and the trial continues. Fewer recurrences on a combined endpoint is a substantial finding; it is not the same as a proven survival benefit. The full presentation is still slated for Saturday at the ESMO Congress in Madrid, which will give the market its next real opportunity to weigh the data.
Should investors sell immediately? Or is it worth buying Moderna?
A split-adjusted move, not a verdict on the therapy
One point needs stating plainly: the 17% decline is an adjustment-driven price move, and shareholder value is unchanged by the mechanics of it. It is not evidence of panic, nor a judgment that the treatment does not work. The stock repriced because expectations had run ahead of what the data could support.
Analysts largely praised the results while noting they fell short of elevated market hopes, as the Wall Street Journal reported. Citi's Geoff Meacham reiterated his Sell rating and his $80 price target, calling the data clinically meaningful while flagging inflated expectations around other solid tumor types and any talk of a "cure." Bernstein, by contrast, read the drop as profit-taking after the news and kept its neutral rating. The two views are not mutually exclusive — selling can follow good news precisely because the price had already sprinted ahead of it.
That distinction is sharper than a blanket dismissal of the study. The combination is also being tested in kidney, bladder and lung cancer, where efficacy remains an open question. Extending the melanoma win to those indications in one's head is not sober valuation; it is an extra wager.
The road from data to revenue
Moderna is preparing a US regulatory filing and expects a market launch in 2027, according to AP — a company expectation, not an approval. The Melanoma Institute Australia stressed that the treatment is not currently available and that regulatory review could take several years depending on the country. Those timelines should not blur into a single certainty, and the favorable overall survival trend should not yet be treated as a proven survival advantage.
The economics are just as unsettled. TD Cowen now pegs Moderna's peak profit from personalized cancer therapy at roughly $3.4 billion for 2035, up from a prior estimate of $830 million — a dramatic re-rating, but still a forecast for a distant future. Profits are to be split evenly with Merck, making the partnership as much a part of the calculation as the efficacy itself.
Production adds another variable. The patient-specific manufacturing process currently takes about six weeks, and Moderna is running the approach through at least eight additional cancer studies, including renal cell, bladder and non-small cell lung cancer. Those programs open possibilities without yet supplying proof of a corresponding treatment benefit. A platform can offer several opportunities without every one of them carrying a defensible economic value today.
Moderna has delivered on the medicine. It has not settled the valuation debate. The data justify confidence in the melanoma therapy under study; they do not justify certainty about approval speed, overall survival or other tumor types. For the stock, the size of the hope will matter less than the number of advances actually proven.
Ad
Moderna Stock: New Analysis - 23 October
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
